DCT

2:26-cv-03543

Supernus Pharma Inc v. Zydus Lifesciences Global FZE

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-03543, D.N.J., 04/02/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Zydus USA is incorporated and maintains its principal place of business in New Jersey, and the other defendants have systematic contacts with the district, including through prior litigation and the intent to market the accused products there.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) for generic viloxazine extended-release capsules constitutes an act of infringement of three patents related to methods of treating Attention Deficit/Hyperactivity Disorder (ADHD) and related conditions.
  • Technical Context: The patents relate to the use of viloxazine, a norepinephrine reuptake inhibitor, for treating ADHD, based on a newly identified mechanism of action involving antagonist activity at specific serotonin receptors.
  • Key Procedural History: The complaint notes that the patents-in-suit are listed in the FDA's Orange Book for Plaintiff's approved drug, Qelbree®. The complaint also references a prior, related lawsuit between the parties concerning the same ANDA but different patents, which has been consolidated with other actions. Plaintiff alleges that Defendants' notice letter regarding the patents-in-suit did not contain any noninfringement or invalidity contentions for two of the three asserted patents.

Case Timeline

Date Event
2008-09-05 Priority Date for '753, '143, and '523 Patents
2022-05-10 U.S. Patent No. 11,324,753 Issues
2022-10-04 U.S. Patent No. 11,458,143 Issues
2024-10-22 U.S. Patent No. 12,121,523 Issues
2025-05-27 Defendants send notice letter regarding other patents in prior litigation
2025-06-26 Plaintiff files prior infringement suit against Defendants
2026-03-25 Defendants send Paragraph IV notice letter for patents-in-suit
2026-04-02 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,324,753 - "Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)"

The Invention Explained

  • Problem Addressed: The patent is based on the "unexpected discovery that viloxazine may be effective in the treatment of ADHD in humans with nominal, if any, significant side effects" '753 Patent, col. 1:28-32 While viloxazine was known as an antidepressant that inhibits norepinephrine reuptake, its specific utility and mechanism for ADHD were not established.
  • The Patented Solution: The invention claims a method for treating ADHD by administering viloxazine, which the inventor discovered exhibits a previously unknown dual-receptor antagonist activity at the 5-HT7 and 5-HT1B serotonin receptors, in addition to its known noradrenergic activity '753 Patent, col. 2:57-61 The patent provides data from receptor binding assays to demonstrate this specific antagonist effect '753 Patent, FIGS. 3, 6
  • Technical Importance: The claimed invention provides a new pharmacological basis for using viloxazine to treat ADHD, moving beyond its known properties as a simple norepinephrine reuptake inhibitor to a more complex, multi-receptor mechanism of action '753 Patent, col. 1:43-48

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims without specifying them Compl. ¶67 Independent claim 1 is representative.
  • Independent Claim 1 Elements:
    • A method of antagonizing 5-HT7 and 5HT1B receptor activity in a patient suffering from ADHD,
    • consisting of administering to the patient in need thereof a therapeutically effective amount of viloxazine,
    • wherein the administration antagonizes both receptors.

U.S. Patent No. 11,458,143 - "Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)"

The Invention Explained

  • Problem Addressed: As a continuation of the same patent family, the '143 Patent addresses the same technical context as the '753 Patent: providing an effective treatment for ADHD using viloxazine '143 Patent, col. 1:29-34
  • The Patented Solution: The patent claims a method of treating ADHD by administering viloxazine. The underlying discovery remains the compound's multi-faceted receptor activity, including its antagonist effects at serotonin receptors and its known noradrenergic reuptake inhibition '143 Patent, col. 2:59-63
  • Technical Importance: This patent broadens the protection around the use of viloxazine for ADHD by claiming the treatment method itself, grounded in the pharmacological discoveries detailed in the specification.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims without specifying them Compl. ¶90 Independent claim 1 is representative.
  • Independent Claim 1 Elements:
    • A method of treating a patient suffering from ADHD,
    • consisting of administering to the patient in need thereof a therapeutically effective amount of viloxazine or a pharmaceutically acceptable salt thereof in a formulation.

U.S. Patent No. 12,121,523 - "Method of Treatment of Attention Deficit/Hyperactivity Disorder (ADHD)"

Technology Synopsis

The '523 patent, also part of the same family, is directed to methods of treating patients who have ADHD co-morbid with other mood or affective disorders, such as anxiety or depression '523 Patent, col. 1:23-29 The solution is the administration of viloxazine, which the patent teaches is effective due to its unique combination of noradrenergic and serotonergic receptor activities '523 Patent, col. 2:33-37

Asserted Claims

The complaint asserts one or more unspecified claims Compl. ¶113 Independent claims 1 and 15 are representative.

Accused Features

The accused features are the instructions for use in the proposed labeling of Defendants' ANDA product, which are expected to substantially copy the label for Qelbree® and allegedly will encourage use that infringes the patent's method claims Compl. ¶121 Compl. ¶122

III. The Accused Instrumentality

Product Identification

Defendants' viloxazine extended-release capsules in 100 mg, 150 mg, and 200 mg dosages, for which Defendants filed Abbreviated New Drug Application (ANDA) No. 220545 with the U.S. Food and Drug Administration (FDA) Compl. ¶4 Compl. ¶48 Compl. ¶59

Functionality and Market Context

  • The ANDA Products are a generic version of Plaintiff's Qelbree®, which is a selective norepinephrine reuptake inhibitor Compl. ¶40 Compl. ¶47 The complaint alleges that Defendants' proposed prescribing information indicates the product for the "treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older" Compl. ¶52
  • The proposed label for the ANDA Products includes detailed dosage and administration instructions for different patient populations, which allegedly mirror the instructions for Qelbree® Compl. ¶53 The infringement alleged is the statutory act of filing the ANDA to seek approval for a product whose labeled use, if marketed, would infringe the patents-in-suit Compl. ¶71 Compl. ¶94 Compl. ¶117

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

11,324,753 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of antagonizing 5-HT7 and 5HT1B receptor activity... The proposed product contains viloxazine, which the patent asserts has antagonist activity at these receptors. The proposed label allegedly encourages administration that will result in this activity. ¶77 col. 2:57-61
...in a patient suffering from ADHD... The proposed product label explicitly states the product is "indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD)". ¶52 col. 1:39-42
...consisting of administering to the patient...a therapeutically effective amount of viloxazine... The proposed product label contains detailed instructions for administering specific oral dosages of viloxazine (e.g., 100 mg or 200 mg once daily) for the treatment of ADHD. ¶53 col. 5:13-17
...wherein the administration antagonizes both receptors. The administration of viloxazine, an inherent property of the active ingredient, is alleged to result in the antagonism of the 5-HT7 and 5-HT1B receptors as taught in the patent. ¶76 col. 7:17-18

11,458,143 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating a patient suffering from ADHD... The proposed product label explicitly states the product is "indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD)". ¶52 col. 1:29-34
...consisting of administering to the patient...a therapeutically effective amount of viloxazine or a pharmaceutically acceptable salt thereof in a formulation. The proposed product is a viloxazine extended-release capsule, and the proposed label provides specific dosage instructions for its administration to treat ADHD. ¶48; ¶53 col. 5:20-24

Identified Points of Contention:

  • Technical Questions: For the '753 Patent, a potential issue is what evidence is required to demonstrate that the administration of the accused generic product results in the claimed "antagonizing" of both the 5-HT7 and 5-HT1B receptors. The infringement theory relies on an inherent property of the drug substance, which a defendant may challenge as not being a guaranteed outcome of the labeled method of treatment.
  • Scope Questions: The infringement allegation for the '143 Patent appears to map directly onto the accused product's proposed indication and dosage instructions. The analysis may focus less on technical mismatches and more on potential invalidity arguments (which the complaint alleges Defendants have not yet raised for this patent) Compl. ¶37

V. Key Claim Terms for Construction

  • The Term: "antagonizing" / "antagonizes" (from '753 Patent, claim 1)
  • Context and Importance: This term is the central limitation distinguishing the '753 Patent's claims from a general method of using viloxazine. The infringement analysis depends on whether the administration of the accused product necessarily performs this specific pharmacological function. Practitioners may focus on this term because it requires linking the administration of a drug to a specific receptor-level mechanism of action.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent specification describes the discovery that "viloxazine exhibits specific antagonist activity at the 6-HT7 (serotonin 7) and 5HT1B receptors" without quantifying a required level of activity for the claim '753 Patent, col. 2:57-61 This could support an interpretation where any measurable antagonist activity meets the claim limitation.
    • Evidence for a Narrower Interpretation: The detailed description provides specific results from functional assays, including IC50 values derived from competition curves '753 Patent, FIGS. 3, 6 '753 Patent, col. 5:8-12 A party could argue that "antagonizes" should be construed to require a level of activity consistent with that demonstrated in the patent's examples, potentially limiting the claim's scope.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that by seeking approval for their ANDA Products with proposed labeling that instructs and encourages physicians to prescribe and patients to use the product to treat ADHD, Defendants will actively induce infringement of the patented methods upon FDA approval Compl. ¶¶76-79 Compl. ¶¶99-102 Compl. ¶¶122-125
  • Willful Infringement: Willfulness is alleged based on Defendants' knowledge of the patents-in-suit, evidenced by their filing of a Paragraph IV certification that specifically references each patent Compl. ¶81 Compl. ¶104 Compl. ¶127 The complaint asserts Defendants acted without a reasonable basis for believing they would not be liable for infringement Compl. ¶81

VII. Analyst's Conclusion: Key Questions for the Case

  1. A core issue will be one of pharmacological mechanism: For the '753 Patent, what level of evidence is required to prove that the administration of Defendants' generic product performs the claimed method of "antagonizing" the 5-HT7 and 5-HT1B receptors? The dispute may turn on whether this is an inherent and unavoidable consequence of the labeled use.
  2. A second key issue will be the impact of Defendants' Paragraph IV notice: The complaint alleges Defendants' notice letter for the '753 and '143 patents failed to include the statutorily required detailed statement of non-infringement or invalidity Compl. ¶37 A central question will be what legal effect, if any, this alleged omission has on Defendants' ability to later contest infringement or validity of those patents.
  3. A final question will be one of patent validity: Although not detailed in the complaint, the underlying dispute in any ANDA litigation involves the generic applicant's assertion that the patent is invalid or will not be infringed. The resolution of the case will ultimately depend on whether Defendants can prove by clear and convincing evidence that the asserted claims are invalid under §§ 101, 102, 103, or 112.
Loading Complaint